



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



Cytokeratin 19 (m): 293T Lysate: sc-125215

BACKGROUND

Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells and have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. For example, many types of cancer cells express Cytokeratin 19 (CK19), an epithelial cytoskeletal protein within the suprabasal squamous epithelium. Cytokeratin 19 is a specific marker of moderate to severe dysplasia and carcinoma *in situ* in oral cavity squamous epithelium, and measurement of Cytokeratin 19 may be a useful marker in diagnosing hepatoma. Cytokeratin 19 fragment levels in serum have been documented as a marker for lung cancer. Clinical investigations have suggested that serum CYFRA 21-1, a fragment of Cytokeratin 19, may be among the most useful tumor markers.

REFERENCES

1. Van Eyken, P., Sciote, R. and Desmet, V.J. 1991. Immunocytochemistry of cytokeratins in primary human liver tumors. *APMIS Suppl.* 23: 77-85.
2. Coltrera, M.D., Zarbo, R.J., Sakr, W.A and Gown, A.M. 1992. Markers for dysplasia of the upper aerodigestive tract. Suprabasal expression of PCNA, p53 and CK19 in alcohol-fixed, embedded tissue. *Am. J. Pathol.* 141: 817-825.
3. van der Velden, L.A., Schaafsma, H.E., Manni, J.J., Ramaekers, F.C. and Kuijpers, W. 1993. Cytokeratin expression in normal and (pre)malignant head and neck epithelia: an overview. *Head Neck* 15: 133-146.
4. Marceau, N. and Loranger, A. 1995. Cytokeratin expression, fibrillar organization and subtle function in liver cells. *Biochem. Cell Biol.* 73: 619-625.
5. Quillien, V., Ramee, M.P., Bansard, J.Y., Meritte, H., Briens, E., Logeais, Y., Langanay, T., Corbineau, H. and Dazard, L. 1995. Serum and tissue distribution of a fragment of Cytokeratin 19 (CYFRA 21-1) in lung cancer patients. *Anticancer Res.* 15: 2857-2863.
6. Mukhopadhyay, T. and Roth, J.A. 1996. Functional inactivation of p53 by antisense RNA induces invasive ability of lung carcinoma cells and down-regulates cytokeratin synthesis. *Anticancer Res.* 16: 1683-1689.
7. Ueda, Y., Fujita, J., Bandoh, S., Hojo, S., Yamaji, Y., Ohtsuki, Y., Dobashi, N. and Takahara, J. 1999. Expression of Cytokeratin 19 mRNA in human lung cancer cell lines. *Int. J. Cancer* 81: 939-943.
8. Nagai, T., Murota, M., Nishioka, M., Fujita, J., Ohtsuki, Y., Dohmoto, K., Hojo, S., Dobashi, N. and Takahara, J. 2001. Elevation of Cytokeratin 19 fragment in serum in patients with hepatoma: its clinical significance. *Eur. J. Gastroenterol. Hepatol.* 13: 157-161.
9. Wu, F., Fujita, J., Murota, M., Li, J.Q., Ishida, T., Nishioka, M., Imaida, Y. and Kuriyama, S. 2002. CYFRA 21-1 is released in TNF α -induced apoptosis in the hepatocellular carcinoma cell line HuH-7. *Int. J. Oncol.* 21: 441-445.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

CHROMOSOMAL LOCATION

Genetic locus: Krt19 (mouse) mapping to 11 D.

PRODUCT

Cytokeratin 19 (m): 293T Lysate represents a lysate of mouse Cytokeratin 19 transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

APPLICATIONS

Cytokeratin 19 (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive Cytokeratin 19 antibodies. Recommended use: 10-20 μ l per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.